ABBV-295
Sources
registry, as of 2026-10-27Stale
https://clinicaltrials.gov/study/NCT07752979
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities. Overall status RECRUITING. Phases PHASE2. Lead sponsor AbbVie. Enrollment 360. Conditions Obesity; Overweight. Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to evaluate the effect of various doses of ABBV-295 compared to placebo on reducing body weight at Week 32 in participants with obesit
ClinicalTrials.gov NCT07752979 protocol and results modules
registry, as of 2026-11-05
https://clinicaltrials.gov/study/NCT07291232
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE1. Lead sponsor AbbVie. Enrollment 80. Conditions Obesity. This study is to assess adverse events, change in body weight and pharmacokinetics in adult participants with obesity receiving ABBV-295 subcutaneous injections or matching placebo.
ClinicalTrials.gov NCT07291232 protocol and results modules
registry, as of 2026-08-14Stale
https://clinicaltrials.gov/study/NCT07514260
A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE1. Lead sponsor AbbVie. Enrollment 24. Conditions Healthy Volunteer. The purpose of this study is to assess the adverse events, tolerability, and Pharmacokinetics (PK) of subcutaneous injections of ABBV-295 in healthy adult Japanese participants with overweight or obesity.
ClinicalTrials.gov NCT07514260 protocol and results modules
registry, as of 2026-08-31Stale
https://clinicaltrials.gov/study/NCT07414784
A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives. Overall status COMPLETED. Phases PHASE1. Lead sponsor AbbVie. Enrollment 20. Conditions Healthy Volunteer. This Study of ABBV-295 subcutaneous injections will assess pharmacokinetics and adverse events in healthy adult women participants with overweight or obesity taking oral contraceptives.
ClinicalTrials.gov NCT07414784 protocol and results modules
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT07752979
32 in participants with obesity or overweight with weight-related comorbidities. ABBV-295 is an investigational long-acting amylin analog being developed for chronic weight management. Participants are placed into multiple treatment groups with different dosing paradigms of ABBV-295 or placebo. Participants will not
NCT07752979 description or intervention text